Lymphoma Patient Education and Engagement Seminar- Sydney 2023

Upcoming Education Event in Sydney 

Join us on 24th October at the Shangri La Hotel, Sydney for this session where we will delve into the topic of – Wellbeing Through Treatment and Beyond – with Dr Toni Lindsay.  We will then explore the latest advancements in treatment in 2023, focusing on cutting-edge treatments through clinical trials – with Professor Judith Trotman.  Don’t miss this opportunity to gain valuable insights, share experiences, and find hope in the company of your community.

Speaker information:

Professor Judith Trotman (MBChB, FRACP, FRCPA), is Head of Haematology, Concord Repatriation General Hospital, University of Sydney, Australia. Dr Trotman is committed to embedding lymphoma research into world-class clinical care as the founding Director (2004-2019), of the Concord Hospital Haematology Clinical Research Unit. Her research is characterised by a commitment to focusing on current priorities of lymphoma patients. Professor Trotman is also the current Chair of the ALLG Clinical Trials Unit.

Dr Toni Lindsay is a Senior Clinical Psychologist who has been working with both adults and adolescents in an oncology setting since 2007. She works at Chris O’ Brien Lifehouse in the Oncology service and is a specialist in the care of Adolescents and Young Adults with cancer. Toni teaches in the Department of Adolescent Medicine at the University of Melbourne and the University of Sydney Nursing School. She is the chair of the International Psycho-Oncology for Adolescent and Young Adult Cancer Care Group, and is actively involved in several multisite research projects. Toni has published three books. The Certainty Myth has been released in Sept 2022 and like her other two books, ‘Cancer, Sex, Drugs and Death’ (2017) and ‘The Cancer
Companion’ (2021) are about the use of Acceptance and Commitment Therapy (ACT).

Places are limited, so get in quickly and follow the link below to register.

 

Note: This is an in person event only

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Tuesday 24th of October 2023
Time: 12:30pm AEDT - 2:30pm AEDT

Support and information

Contact Lymphoma Australia Today!

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.